IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Lifted by Telos Capital Management Inc.

Telos Capital Management Inc. raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,747 shares of the medical research company’s stock after purchasing an additional 514 shares during the period. Telos Capital Management Inc.’s holdings in IQVIA were worth $9,182,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in IQV. Versant Capital Management Inc raised its position in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new position in shares of IQVIA during the 2nd quarter valued at $27,000. Park Place Capital Corp acquired a new stake in shares of IQVIA in the 3rd quarter valued at $28,000. Itau Unibanco Holding S.A. bought a new stake in IQVIA in the second quarter worth $29,000. Finally, Riverview Trust Co acquired a new position in IQVIA during the first quarter worth $32,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IQV has been the subject of a number of analyst reports. Barclays reduced their price target on IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research report on Tuesday, October 15th. Redburn Atlantic initiated coverage on IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 target price for the company. Royal Bank of Canada began coverage on shares of IQVIA in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price target on the stock. Robert W. Baird upped their price objective on shares of IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a report on Friday, September 20th. Finally, Evercore ISI dropped their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $267.87.

IQVIA Trading Down 2.3 %

Shares of IQV opened at $231.22 on Tuesday. The stock’s 50-day moving average price is $239.07 and its 200 day moving average price is $231.03. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The firm has a market capitalization of $42.15 billion, a price-to-earnings ratio of 30.03, a P/E/G ratio of 2.26 and a beta of 1.49. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. During the same period in the prior year, the company posted $2.22 earnings per share. IQVIA’s revenue was up 2.3% on a year-over-year basis. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.